NIH clinical trial of investigational vaccine for COVID-19 begins

23 Mar, 2020

Electronic microscope image of SARS-CoV2

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) is funding a Phase 1 open-label clinical trial about a new vaccine against COVID-19 with 45 healthy volunteers over 6 weeks. 
The new vaccine, the mRNA-1273, will be evaluated at a different doses as well as the capability of inducing an immune response.
This first phase will recquire participants to receive two doses of the vaccine via intramuscular injection, receiving a 25 microgram, 100 or 250 mcg dose at both vaccinations, with 15 people in each cohort. 

Sign up to leave a comment